clinical trial · NCT05330182
LMN-201 for Prevention of C. Difficile Infection Recurrence
Lumen Bioscience, Inc.·phase3·recruiting·n = 375
Clostridioides Difficile InfectionLMN-201Placebo
brief summary
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
started
Aug 29, 2024
primary completion
Jun 1, 2027
completion
Dec 1, 2027
last updated
Feb 10, 2026
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol